Achillion Pharmaceuticals, Inc.
300 George Street
New Haven
Connecticut
06511
United States
Tel: 203-624-7000
Fax: 203-624-7003
Website: http://www.achillion.com/
254 articles about Achillion Pharmaceuticals, Inc.
-
Achillion Pharmaceuticals, Inc. Shows Potential For "Best-In-Disease" HCV Regimen - 100% SVR4 Following A Dual 6-Week ACH-3102-Based Regimen And Separately A 4.8 Log10 Reduction With ACH-3422
12/22/2014
-
Why Gilead Sciences, Inc. And AbbVie Are Keeping An Eye On Achillion Pharmaceuticals, Inc.
12/15/2014
-
Achillion Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences
11/25/2014
-
Achillion Pharmaceuticals, Inc. Reports 100% SVR12 In A Phase 2 Combination Study With ACH-3102 At The Liver Meeting 2014 (American Association for Study of Liver Diseases)
11/10/2014
-
Achillion Pharmaceuticals, Inc. Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform At The 56th Annual Meeting Of The American Society of Hematology
11/6/2014
-
Achillion Pharmaceuticals, Inc. Reports Third Quarter And Nine Month 2014 Financial Results
11/4/2014
-
Achillion Pharmaceuticals, Inc. To Present Updated Clinical HCV Data On ACH-3102 And Preclinical Profile Of ACH-3422 At The American Association for Study of Liver Diseases Annual Meeting
10/8/2014
-
Achillion Pharmaceuticals, Inc. Hits One Year High After Rumors Gilead Sciences, Inc. Might Buy It Out
8/28/2014
-
Gilead Sciences, Inc. Shaky As Achillion Pharmaceuticals, Inc.'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial
8/27/2014
-
Achillion Pharmaceuticals, Inc. Granted U.S. Patent For ACH-3102 And Structurally Related NS5A Inhibitors
8/20/2014
-
Achillion Pharmaceuticals, Inc. Reports Second Quarter And Six Month 2014 Financial Results
8/8/2014
-
Achillion Pharmaceuticals, Inc. Added To The Russell 2000 And Russell Microcap Indexes
7/2/2014
-
AbbVie And Johnson & Johnson Were In A Bidding War For Idenix Pharmaceuticals, Inc., Will Achillion Pharmaceuticals, Inc. Be The Next Target?
6/13/2014
-
Achillion Pharmaceuticals, Inc. To Present At Two Upcoming Investor Conferences
6/11/2014
-
Achillion Pharmaceuticals, Inc. Surges As The FDA Lifts Hold On Hepatitis C Trial; Stock Up +83.29% At Market Close (June 10, 2014)
6/11/2014
-
Achillion Pharmaceuticals, Inc. Reports First Quarter 2014 Financial Results
5/7/2014
-
Achillion Pharmaceuticals, Inc. To Present At Three Upcoming Investor Conferences
5/1/2014
-
Achillion Pharmaceuticals, Inc. Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, For HCV
5/1/2014
-
Achillion Pharmaceuticals, Inc. Announces Oral Presentations Given At APASL 2014 Detailing Clinical Activity Of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
3/14/2014
-
Achillion Pharmaceuticals, Inc. Reports 2013 Fourth Quarter And Year-End Financial Results
3/7/2014